Gaucher disease: A systematic review and meta-analysis of bone complications and their response to treatment

Journal of Inherited Metabolic Disease

Volumn 33, Issue 3, 2010, Pages 271-279

  Piran, Siavash ^a   Amato, Dominick ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; GLYCOSIDASE; MIGLUSTAT; UNCLASSIFIED DRUG; VELAGLUCERASE; 1 DEOXYNOJIRIMYCIN;

BONE DENSITY; BONE DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW; ADULT; ANALOGS AND DERIVATIVES; BONE; BONE MARROW; INTERVENTION STUDY; LUMBAR VERTEBRA; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; TIME; TREATMENT OUTCOME;

1-DEOXYNOJIRIMYCIN; ADULT; BONE AND BONES; BONE DENSITY; BONE MARROW; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; HUMANS; INTERVENTION STUDIES; LUMBAR VERTEBRAE; MAGNETIC RESONANCE IMAGING; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953231584     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9071-0     Document Type: Review

References (45)

1. E Arnheim G Chicco M Phillips, et al. 2008 Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone density Rheumatol Int 28 9 873 877 10.1007/s00296-008-0550-7 18317771
2. E Beutler A Demina K Laubscher, et al. 1995 The clinical course of treated and untreated Gaucher disease. A study of 45 patients Blood Cells Mol Dis 21 86 108 10.1006/bcmd.1995.0012 1:STN:280:DyaK287htlKqsw%3D%3D 8846048
3. J Charrow B Dulisse GA Grabowski NJ Weinreb 2007 The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease Clin Genet 71 205 211 10.1111/j.1399-0004.2007.00769.x 1:STN:280:DC%2BD2s7htVaruw%3D%3D 17309642 (Pubitemid 46322658)
4. M Chen J Wang 2008 Gaucher disease: review of the literature Arch Pathol Lab Med 132 851 853 18466035
5. G Ciana R Addobbati G Tamaro, et al. 2005 Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy J Inherit Metab Dis 28 723 732 10.1007/s10545-005- 0032-y 1:CAS:528:DC%2BD2MXpvVWqu74%3D 16151904 (Pubitemid 41349260)
6. T Cox R Lachmann C Hollak, et al. 2000 Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis Lancet 355 1481 1485 10.1016/S0140-6736(00)02161-9 1:CAS:528:DC%2BD3cXjt1alt7g%3D 10801168
7. F Curtin DG Altman D Elbourne 2002 Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes Stat Med 21 15 2131 2144 10.1002/sim.1205 12210629 (Pubitemid 34830752)
8. M de Fost CE Hollak JE Groener, et al. 2006 Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood 108 830 835 10.1182/blood-2005-12-5072 16527890 (Pubitemid 44154614)
9. M de Fost CJ van Noesel JM Aerts M Maas RG Pöll CE Hollak 2008 Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy Haematologica 93 1119 1120 10.3324/haematol.12651 18519519 (Pubitemid 351957043)
10. D Elstein A Zimran 2009 Review of the safety and efficacy of imiglucerase treatment of Gaucher disease Biologics 3 407 417 1:CAS:528:DC%2BD1MXhsVyksb3F 19774208
11. D Elstein A Abrahamov I Hadas-Halpern A Meyer A Zimran 1998 Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease QJM 91 483 488 10.1093/qjmed/91.7.483 1:STN:280:DyaK1M%2FhsVKltw%3D%3D 9797931
12. D Elstein C Hollak JM Aerts, et al. 2004 Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease J Inherit Metab Dis 27 757 766 10.1023/B:BOLI.0000045756.54006.17 1:CAS:528:DC%2BD2cXovVOjsLw%3D 15505381 (Pubitemid 39433603)
13. D Elstein A Dweck D Attias, et al. 2007 Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement Blood 110 2296 2301 10.1182/blood-2007-02-075960 1:CAS:528:DC%2BD2sXhtFCnsbzI 17609429 (Pubitemid 47523147)
14. A El-Beshlawy L Ragab I Youssry, et al. 2006 Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients J Inherit Metab Dis 29 92 98 10.1007/s10545-006-0121-6 1:CAS:528:DC%2BD28XjtlWgtbc%3D 16601874
15. P Giraldo P Latre P Alfonso, et al. 2006 Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease Haematologica 91 703 706 1:CAS:528: DC%2BD28Xls1SrtLk%3D 16627252
16. GA Grabowski NW Barton G Pastores, et al. 1995 Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources Ann Intern Med 122 33 39 1:STN:280:DyaK2M%2FnslaisA%3D%3D 7985893
17. GA Grabowski N Leslie R Wenstrup 1998 Enzyme therapy for Gaucher disease: the first 5 years Blood Rev 12 115 133 10.1016/S0268-960X(98)90023-6 1:STN:280:DyaK1czis1CntA%3D%3D 9661800 (Pubitemid 28327418)
18. P Guggenbuhl B Grosbois G Chalès 2008 Gaucher disease Joint Bone Spine 75 116 124 10.1016/j.jbspin.2007.06.006 1:CAS:528:DC%2BD1cXmsFCjtrw%3D 17996473
19. CE Hollak JM Aerts R Goudsmit, et al. 1995 Individualised low-dose alglucerase therapy for type 1 Gaucher disease Lancet 345 1474 1478 10.1016/S0140-6736(95)91037-9 1:CAS:528:DyaK28XjvFCg 7769902
20. C Hollak M Maas E Akkerman A den Heeten H Aerts 2001 Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease Blood Cells Mol Dis 27 1005 1012 10.1006/bcmd.2001.0474 1:STN:280:DC%2BD387js1Wisw%3D%3D 11831867 (Pubitemid 34163969)
21. H Hůlková J Ledvinová H Poupetová A Kohout V Malinová M Elleder 2009 Autopsy case of Gaucher disease type I in a patient on enzyme replacement therapy. Comments on the dynamics of persistent storage process J Inherit Metab Dis. 32 4 551 559 10.1007/s10545-009-1178-9 19557545
22. LA Johnson BE Hoppel EL Gerard, et al. 1992 Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease Radiology 182 2 451 455 1:STN:280:DyaK387itlyqsQ%3D%3D 1732964
23. E Lebel A Dweck AJ Foldes, et al. 2004 Bone density changes with enzyme therapy for Gaucher disease J Bone Miner Metab 22 597 601 10.1007/s00774-004- 0529-8 15490271 (Pubitemid 39517881)
24. M Maas LW Poll MR Terk 2002 Imaging and quantifying skeletal involvement in Gaucher disease Br J Radiol 75 1 A13 A24 12036829
25. M Maas CE Hollak EM Akkerman JM Aerts J Stoker GJ Den Heeten 2002 Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter AJR Am J Roentgenol 179 4 961 965 12239046
26. M Maas C van Kuijk J Stoker, et al. 2003 Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience Radiology 229 554 561 10.1148/radiol.2292020296 14526090 (Pubitemid 37310846)
27. P Mikosch M Reed R Baker, et al. 2008 Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with Imiglucerase and Miglustat Calcif Tissue Int 83 1 43 54 10.1007/s00223-008-9143-4 1:CAS:528:DC%2BD1cXhtVSgurjP 18553043
28. PK Mistry P Deegan A Vellodi JA Cole M Yeh NJ Weinreb 2009 Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis Br J Haematol 147 4 561 570 10.1111/j.1365-2141.2009.07872.x 1:CAS:528:DC%2BD1MXhsFKjtbzJ 19732054
29. E Olsen K McHugh A Vellodi 2003 Routine magnetic resonance imaging of the spine in children with Gaucher disease: does it help therapeutic management? Pediatr Radiol 33 782 785 10.1007/s00247-003-1051-1 (Pubitemid 37369192)
30. MS Parisi SR Mastaglia A Bagur G Goldstein SN Zeni B Oliveri 2008 Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase Eur J Med Res 13 1 31 38 1:CAS:528:DC%2BD1cXkt1yjtLo%3D 18226995
31. GM Pastores AR Sibille GA Grabowski 1993 Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months Blood 82 408 416 1:STN:280:DyaK3szitVCiug%3D%3D 8392397
32. GM Pastores NL Barnett EH Kolodny, et al. 2005 An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment Clin Ther 27 1215 1227 10.1016/j.clinthera.2005.08.004 1:CAS:528:DC%2BD2MXhtFWgurfM 16199246 (Pubitemid 41393915)
33. GM Pastores D Elstein M Hrebícek A Zimran 2007 Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies Clin Ther 29 1645 1654 10.1016/j.clinthera.2007.08.006 1:CAS:528:DC%2BD2sXhtFyjt7jK 17919546 (Pubitemid 47494543)
34. LW Poll JA Koch S vom Dahl, et al. 2001 Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results Skeletal Radiol 30 496 503 10.1007/s002560100375 1:STN:280:DC%2BD3MrktVOitw%3D%3D 11587517 (Pubitemid 32894331)
35. LW Poll JA Koch R Willers, et al. 2002 Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients Blood Cells Mol Dis 28 209 220 10.1006/bcmd.2002.0511 12064917 (Pubitemid 34743755)
36. PL Robertson M Maas J Goldblatt 2007 Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score AJR Am J Roentgenol 188 1521 1528 10.2214/AJR.06.1410 17515371 (Pubitemid 46866853)
37. M Roca J Mota P Alfonso M Pocoví P Giraldo 2007 S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease Eur J Radiol 62 1 132 137 10.1016/j.ejrad.2006.11.024 1:STN:280:DC%2BD2s7mvFOltA%3D%3D 17161930 (Pubitemid 46413626)
38. DI Rosenthal SH Doppelt HJ Mankin, et al. 1995 Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase Pediatrics 96 629 637 1:STN:280:DyaK28%2FgtVWmsg%3D%3D 7567322
39. R Schiffmann H Mankin JM Dambrosia, et al. 2002 Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy Blood Cells Mol Dis 28 2 288 296 10.1006/bcmd.2002.0517 12064924 (Pubitemid 34743762)
40. KB Sims GM Pastores NJ Weinreb, et al. 2008 Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study Clin Genet 73 430 440 10.1111/j.1399-0004.2008.00978.x 1:STN:280: DC%2BD1c3jvFCmsw%3D%3D 18312448 (Pubitemid 351517258)
41. MR Terk S Dardashti HA Liebman 2000 Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume Skeletal Radiol 29 563 571 10.1007/s002560000276 1:STN:280:DC%2BD3M7jslSmtA%3D%3D 11127678
42. RR van Rijn IM van der Sluis TM Link, et al. 2003 Bone densitometry in children: a critical appraisal Eur Radiol 13 4 700 710 12664106
43. NJ Weinreb MD Cappellini TM Cox, et al. 2010 A validated disease severity scoring system for adults with type 1 Gaucher disease Genet Med 12 1 44 51 10.1097/GIM.0b013e3181c39194 20027115
44. RJ Wenstrup KA Kacena P Kaplan, et al. 2007 Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease J Bone Miner Res 22 119 126 10.1359/jbmr.061004 1:CAS:528:DC%2BD2sXhtVWnur0%3D 17032149 (Pubitemid 46032604)
45. C Wilson R Spearing L Teague P Robertson H Blacklock 2007 The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy Mol Genet Metab 92 131 136 10.1016/j.ymgme.2007. 05.013 1:CAS:528:DC%2BD2sXhtVWmt7fF 17604204 (Pubitemid 47361892)